Search

Your search keyword '"Poisson, Laila M."' showing total 314 results

Search Constraints

Start Over You searched for: Author "Poisson, Laila M." Remove constraint Author: "Poisson, Laila M."
314 results on '"Poisson, Laila M."'

Search Results

1. Glioma progression is shaped by genetic evolution and microenvironment interactions

2. Development of ‘Core Outcome Sets’ for Meningioma in Clinical Studies (The COSMIC Project): protocol for two systematic literature reviews, eDelphi surveys and online consensus meetings

3. Association of partial T2-FLAIR mismatch sign and isocitrate dehydrogenase mutation in WHO grade 4 gliomas: results from the ReSPOND consortium

4. Detection of diagnostic and prognostic methylation-based signatures in liquid biopsy specimens from patients with meningiomas

5. Longitudinal molecular trajectories of diffuse glioma in adults

6. Imaging and diagnostic advances for intracranial meningiomas.

7. Molecular and translational advances in meningiomas

8. Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium

9. An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics

10. The TSHS Resources Portal: A Source of Real and Relevant Data for Teaching Statistics in the Health Sciences

11. A guide to successful management of collaborative partnerships in quantitative research: An illustration of the science of team science

12. Table S1 from The Epigenetic Evolution of Glioma Is Determined by the IDH1 Mutation Status and Treatment Regimen

13. Supp Figures from The Epigenetic Evolution of Glioma Is Determined by the IDH1 Mutation Status and Treatment Regimen

14. Supplemental Figures Legends from The Epigenetic Evolution of Glioma Is Determined by the IDH1 Mutation Status and Treatment Regimen

15. Data from The Epigenetic Evolution of Glioma Is Determined by the IDH1 Mutation Status and Treatment Regimen

16. Supplementary Appendix from The Epigenetic Evolution of Glioma Is Determined by the IDH1 Mutation Status and Treatment Regimen

17. The Epigenetic Evolution of Glioma Is Determined by the IDH1 Mutation Status and Treatment Regimen

19. Utility of an Untargeted Metabolomics Approach Using a 2D GC-GC-MS Platform to Distinguish Relapsing and Progressive Multiple Sclerosis.

20. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas

23. The epigenetic evolution of glioma is determined by the IDH1 mutation status and treatment regimen

24. NIMG-13. ROBUSTNESS OF PROGNOSTIC STRATIFICATION IN DE NOVO GLIOBLASTOMA PATIENTS ACROSS 22 GEOGRAPHICALLY DISTINCT INSTITUTIONS: INSIGHTS FROM THE RESPOND CONSORTIUM

25. EPID-15. SEX-SPECIFIC DIFFERENCES IN GLIOBLASTOMA IN THE RESPOND CONSORTIUM

26. An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics

27. The Somatic Genomic Landscape of Glioblastoma

32. Discordant inheritance of chromosomal and extrachromosomal DNA elements contributes to dynamic disease evolution in glioblastoma

33. Table S4 from T2–FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project

34. Figure S1 from T2–FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project

40. The Somatic Genomic Landscape of Glioblastoma

43. Blood-based untargeted metabolomics in relapsing-remitting multiple sclerosis revealed the testable therapeutic target

44. Supplement to: Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas.

45. Divergent Metabolic Effects of Metformin Merge to Enhance Eicosapentaenoic Acid Metabolism and Inhibit Ovarian Cancer In Vivo

46. Detection of tumor-specific DNA methylation markers in the blood of patients with pituitary neuroendocrine tumors

Catalog

Books, media, physical & digital resources